FENNEC PHARMACEUTICALS INC (FRX.CA) Fundamental Analysis & Valuation

TSX:FRX • CA31447P1009

9.87 CAD
-0.48 (-4.64%)
Last: Mar 9, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This FRX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to FRX. FRX was compared to 23 industry peers in the Biotechnology industry. While FRX seems to be doing ok healthwise, there are quite some concerns on its profitability. FRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. FRX.CA Profitability Analysis

1.1 Basic Checks

  • FRX had negative earnings in the past year.
  • In the past year FRX has reported a negative cash flow from operations.
  • FRX had negative earnings in each of the past 5 years.
  • FRX had negative operating cash flow in 4 of the past 5 years.
FRX.CA Yearly Net Income VS EBIT VS OCF VS FCFFRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

  • FRX's Return On Assets of -14.09% is fine compared to the rest of the industry. FRX outperforms 73.91% of its industry peers.
Industry RankSector Rank
ROA -14.09%
ROE N/A
ROIC N/A
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FRX.CA Yearly ROA, ROE, ROICFRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800

1.3 Margins

  • The Gross Margin of FRX (93.12%) is better than 100.00% of its industry peers.
  • The Profit Margin and Operating Margin are not available for FRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FRX.CA Yearly Profit, Operating, Gross MarginsFRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. FRX.CA Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for FRX has been increased compared to 1 year ago.
  • The number of shares outstanding for FRX has been increased compared to 5 years ago.
  • FRX has a better debt/assets ratio than last year.
FRX.CA Yearly Shares OutstandingFRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FRX.CA Yearly Total Debt VS Total AssetsFRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -2.25, we must say that FRX is in the distress zone and has some risk of bankruptcy.
  • FRX has a Altman-Z score (-2.25) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.25
ROIC/WACCN/A
WACCN/A
FRX.CA Yearly LT Debt VS Equity VS FCFFRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 4.69 indicates that FRX has no problem at all paying its short term obligations.
  • FRX has a better Current ratio (4.69) than 82.61% of its industry peers.
  • FRX has a Quick Ratio of 4.44. This indicates that FRX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of FRX (4.44) is better than 82.61% of its industry peers.
Industry RankSector Rank
Current Ratio 4.69
Quick Ratio 4.44
FRX.CA Yearly Current Assets VS Current LiabilitesFRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. FRX.CA Growth Analysis

3.1 Past

  • The earnings per share for FRX have decreased strongly by -475.00% in the last year.
  • Looking at the last year, FRX shows a very negative growth in Revenue. The Revenue has decreased by -21.39% in the last year.
EPS 1Y (TTM)-475%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.48%
Revenue 1Y (TTM)-21.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%78.69%

3.2 Future

  • FRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 219404.00% yearly.
  • FRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.26% yearly.
EPS Next Y-238870924235731040%
EPS Next 2Y11024322499.71%
EPS Next 3Y27280900%
EPS Next 5Y219404%
Revenue Next Year-20.03%
Revenue Next 2Y16.86%
Revenue Next 3Y19.53%
Revenue Next 5Y28.26%

3.3 Evolution

FRX.CA Yearly Revenue VS EstimatesFRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M
FRX.CA Yearly EPS VS EstimatesFRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

3

4. FRX.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FRX. In the last year negative earnings were reported.
  • FRX is valuated reasonably with a Price/Forward Earnings ratio of 10.79.
  • Based on the Price/Forward Earnings ratio, FRX is valued cheaply inside the industry as 91.30% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 24.39. FRX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 10.79
FRX.CA Price Earnings VS Forward Price EarningsFRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FRX.CA Per share dataFRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • FRX's earnings are expected to grow with 27280900.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11024322499.71%
EPS Next 3Y27280900%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FRX.CA Dividend Analysis

5.1 Amount

  • No dividends for FRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FRX.CA Fundamentals: All Metrics, Ratios and Statistics

FENNEC PHARMACEUTICALS INC

TSX:FRX (3/9/2026, 7:00:00 PM)

9.87

-0.48 (-4.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)04-01
Inst Owners49.88%
Inst Owner ChangeN/A
Ins Owners2.88%
Ins Owner ChangeN/A
Market Cap337.06M
Revenue(TTM)38.79M
Net Income(TTM)-6.94M
Analysts84.62
Price Target21.4 (116.82%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-95.59%
Min EPS beat(2)-199.56%
Max EPS beat(2)8.37%
EPS beat(4)2
Avg EPS beat(4)-67.7%
Min EPS beat(4)-199.56%
Max EPS beat(4)55.84%
EPS beat(8)3
Avg EPS beat(8)-157.9%
EPS beat(12)5
Avg EPS beat(12)-104.64%
EPS beat(16)6
Avg EPS beat(16)-92.56%
Revenue beat(2)1
Avg Revenue beat(2)3.98%
Min Revenue beat(2)-0.57%
Max Revenue beat(2)8.54%
Revenue beat(4)2
Avg Revenue beat(4)-10.17%
Min Revenue beat(4)-53.52%
Max Revenue beat(4)8.54%
Revenue beat(8)4
Avg Revenue beat(8)-7.28%
Revenue beat(12)6
Avg Revenue beat(12)2.86%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.78%
PT rev (3m)9.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.38%
EPS NY rev (1m)3.7%
EPS NY rev (3m)13.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.79
P/S 6.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)0.91
Fwd EY9.26%
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS1.54
BVpS-0.18
TBVpS-0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.09%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.12%
FCFM N/A
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.69
Quick Ratio 4.44
Altman-Z -2.25
F-Score1
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-475%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.48%
EPS Next Y-238870924235731040%
EPS Next 2Y11024322499.71%
EPS Next 3Y27280900%
EPS Next 5Y219404%
Revenue 1Y (TTM)-21.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%78.69%
Revenue Next Year-20.03%
Revenue Next 2Y16.86%
Revenue Next 3Y19.53%
Revenue Next 5Y28.26%
EBIT growth 1Y-340.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year269.89%
EBIT Next 3Y327.46%
EBIT Next 5YN/A
FCF growth 1Y60.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.53%
OCF growth 3YN/A
OCF growth 5YN/A

FENNEC PHARMACEUTICALS INC / FRX.CA FAQ

What is the ChartMill fundamental rating of FENNEC PHARMACEUTICALS INC (FRX.CA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to FRX.CA.


What is the valuation status of FENNEC PHARMACEUTICALS INC (FRX.CA) stock?

ChartMill assigns a valuation rating of 3 / 10 to FENNEC PHARMACEUTICALS INC (FRX.CA). This can be considered as Overvalued.


What is the profitability of FRX stock?

FENNEC PHARMACEUTICALS INC (FRX.CA) has a profitability rating of 1 / 10.